1 citations
,
February 2022 in “Clinical, Cosmetic and Investigational Dermatology”
In this study, researchers found that the thyroxine receptor agonist TDM10842 accelerated the onset of anagen, a hair growth phase, in C3H mice, potentially through activation of the Wnt/beta-catenin and Hedgehog pathways, with Pclaf playing a key role in this process.
26 citations
,
October 2002 in “Journal of Investigative Dermatology”
This study identifies a mutation in the hairless gene that may impact thyroidreceptor interaction, contributing to alopecia universalis congenita in an Arab Israeli patient.
19 citations
,
October 2009 in “Bioorganic & Medicinal Chemistry Letters”
This study found that a thyroidhormonereceptor ẞ subtype-selective thyromimetic was effective in promoting hair growth in mouse and monkey models when applied topically.
30 citations
,
January 2009 in “Nuclear Receptor Signaling”
This study identified the Hairless (Hr) gene-encoded protein as a corepressor that plays a crucial role in maintaining skin and hair by regulating epithelial stem cell differentiation and gene expression via chromatin remodeling, which may impact both development and disease.
The user discusses their hair loss experience, exploring various hypotheses including thyroid levels, vitamin D, DHEA, nutritional deficiency, diabetes, seborrheic dermatitis, lack of nutrition to hair follicles, chronic inflammation, female pattern hair loss causes, cortisol, and prolactin levels. They are currently using finasteride, beta-sitosterol, and have tried topical dutasteride and microneedling therapy.
GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.
Promising hair loss treatments in 2026 include GT20029, a topical androgen receptor degrader, and VDPHL01, an extended-release oral minoxidil, both offering safer alternatives with fewer side effects. Other treatments like sublingual minoxidil, OND-1, JW0061, TDM-105795, and AMP-303 are also being explored.
The conversation discusses hair loss treatments, focusing on finasteride, minoxidil, and other options like PRP and ketoconazole. It highlights the importance of asking specific questions during a dermatology visit to determine the cause of hair loss and appropriate treatments.
A 29-year-old male experienced hair loss and reduced libido after heavy drinking from 2020 to 2024, and began using finasteride (1mg daily) and minoxidil (5% topical, once daily) in January 2026, noticing thicker hair but no new regrowth after three months. He also introduced derma rolling in February and plans to continue treatment for 6–12 months before fully assessing results.